Sarepta Therapeutics (SRPT) Posts Q1 Loss of 75c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.75), $0.05 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $6.09 million versus the consensus estimate of $3.45 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Chesapeake Utilities plans $1.2B Florida gas pipeline project
• Wolfe Research Upgrades Sarepta Therapeutics (SRPT) to Outperform